"Modern dynamically developing Russian pharmaceutical company being among the leaders in the pharmaceutical industry of the Russian Federation.
In 2022 the company's turnover exceeded 36 billion rubles, with a growth of more than 250%.
Skopinpharm is a developer and manufacturer of medicinal products, one of the major suppliers under the Cost-Intensive Nosologies Program and the largest supplier for Circle of Kindness Foundation providing aid to children with severe and life-threatening disorders.
The company implements two Special Investment Contracts: for the production of blood plasma products and for the treatment of oncological diseases. As part of the implementation of these two contracts, new production and storage buildings are being built, unique technologies for drug production are being transferred, and a plasma storage facility is being built to store plasma for fractionation (raw materials for the production of blood products). At the same time, in partnership with health authorities, a modern system for blood plasma procurement is being created and a program of voluntary blood donation is being developed.
Skopinpharm's success was recognized by the Russian Union of Industrialists and Entrepreneurs for ""Dynamic Business Development"" and ""For Import Substitution Project"".
Skopinpharm facility is located in the Industrial Zone No.1 of Skopin District of Ryazan Region."
EFKO is the largest food producers in Russia, a systemic company of the Russian Federation. The company specializes in the processing of oilseeds (sunflower, soybeans, and rapeseed), production of packaged oils, fats and oleo (special fat), mayonnaise and ketchup. The key trademarks are Sloboda, Pyshka, Altero, and Hi! (abbreviated "healthy innovation"). Production facilities located in the regions of Belgorod, Voronezh, Lipetsk, Sverdlovsk, Krasnodar Krai, as well as the Republic of Kazakhstan, are capable of processing over 4.5 million tons of oilseeds annually. The company actively diversifies its business through its own R&D centre, developing plant-based meat and milk under Hi! brand, and venture investments in food technology and biotechnology.
GEROPHARM is an international biotechnological company with all insulin blockbusters in portfolio.
The company is engaged in the full cycle production of medicines, invests in technological development and the creation of modern pharmaceutical infrastructure.
The company possesses an R&D center, as well as two manufacturing sites of API production and production of finished dosage forms.
The company's portfolio includes original drugs and generics in the areas of neurology, ophthalmology, gynecology and urology, as well as 12 medicines in the area of endocrinology - insulins and hypoglycemic drugs. In 2023 GEROPHARM registered a new drug Semavic® which is the first Russian analogue of Ozempic® that is not supplied to Russia anymore.
Today GEROPHARM is a leader in the Russian insulin market in the areas of its presence.
The company's products are presented not only in Russia, but also in 13 countries of the near and far abroad.
A brief overview of the Nizhpharm Group
The Nizhpharm Group (formerly part of STADA) is one of the biggest Russian manufacturers of high-quality pharmaceuticals with a 105-year history.
The Group’s core business areas are as follows:
The Nizhpharm Group manages the operations of two manufacturing facilities: JSC Nizhpharm in Nizhny Novgorod and LLC Hemofarm in Obninsk. The Group's primary objective is to meet the local needs of patients as a trusted partner in Russia.
The Nizhpharm Group currently employs over 2,200 people.
Our product portfolio includes 120+ items. Approximately third of them are essential and vital drugs.
Akrikhin is the leading Russian pharmaceutical company that has been producing effective, affordable, and high-quality medicines since 1936.
The Company is one of the TOP-5* Russian pharmaceutical manufacturers by sales volume in the retail market.
There are more than 200 pharmaceuticals in the product portfolio. About 45% of products are on the list of vital and essential drugs (VED). All pharmaceuticals belong to the main pharmacotherapeutic areas and are produced in full compliance with international GMP standards.
AKRIKHIN has extensive expertise in the field of dermatology, cardiology, endocrinology, neurology, pediatrics, cosmetology and in the production of vitamin D3. In addition, the company is developing a line of socially significant pharmaceuticals, the INN-Akrikhin portfolio.
All products are proprietary developments of the company's R&D center.
Modern manufacturing complex is located in Staraya Kupavna, office is located in Moscow. The company constantly improves production processes: upgrade production facilities, expand industrial infrastructure, master new technologies and introduce innovations.
The Association of Pharmaceutical Manufacturers of the Eurasian Economic Union is one of the leading associations of domestic manufacturers of medicines, pharmaceutical substances, and vaccines, including those that are full–cycle. The main mission of the organization is to develop innovative drugs in the interest of patients, and, if globally, to participate in the development of a national drug policy, development of the domestic pharmaceutical industry, and strengthening the health of Russian citizens as a whole. The association was registered in 2012, and its main priorities include assisting with the provision of medicine to the population and medical institutions; assisting with the development of pharmaceutical markets in the countries of a unified Eurasian space; and GMP; as well as assisting with scientific research into the development of innovative medicine, vaccines, and other products. To date, the association includes 13 leading domestic pharmaceutical companies
Velpharm Group is a pharmaceutical holding whose development strategy is to create a modern business ecosystem for the full-cycle production of medicinal products.
Velpharm Group consists of several companies, the activity of each is aimed at implementing the overall strategy of the Holding, including 3 production sites:
Velpharm - a pharmaceutical plant for the production of finished drugs in a full cycle:
Velpharm-M - a new research and production complex for the development and production of medicines, which owns its own R&D center (Moscow).
Today, Velpharm Group produces more than 120 socially significant drugs of various dosage forms and different therapeutic categories, more than 70 drugs are at different stages of development and registration.
Mission: working to preserve health and quality of people`s lives by creating modern, effective, safe and affordable medicines.
"Mr. Lyashenko was born in Kazakhstan, where his parents moved from the Alekseevsky district of the Belgorod oblast due to a postgraduate work assignment. After three years, the Lyashenko family returned to their native land.
In 1996, he graduated from Voronezh State University, Faculty of Economics.
He started his career at EFKO as a financial analyst. He shaped EFKO's financial department and was one of the founders of the corporate divisional structure.
Since 2004, he has been in charge of holding operational management as its CEO.
Under Mr. Lyashenko's leadership, all critical areas of EFKO ensuring the sustainability of the business became stronger and separated into independent divisions. These include oil refining, production of food ingredients and branded products, and export sales. Each ensures cutting-edge development and the top ranking of EFKO in the domestic oil processing market.
Largely thanks to the personal contribution of Evgeny Lyashenko, EFKO retains the company's unique focus on developing innovative products. Every day, the company ensures compliance with the status of a systemically important enterprise of the Russian Federation, a two-time winner of the Russian government's Quality Award. And, of course, it produces tasty and healthy products under nationwide loved brands: Sloboda, Altero, and Pyshka. Moreover, since 2020, it has also been developing the Healthy Innovation ESG projects.
Mr. Lyashenko's business and management skills were vital in expanding EFKO's export sales – entering the markets of Turkey, Iran, China, etc."
Born in 1978 in Leningrad.
He has been managing GEROPHARM since 2001. He implemented several strategic initiatives for pharmaceutical supply sustainability and contributed to improved competitiveness of the Russian pharmaceutical sector both within and outside Russia.
Since 2013 he has been a member of the Russian Government Council on Guardianship in Social Sphere, chairing the Health Care and Healthy Lifestyle section. In 2023, he was appointed Deputy to T.A. Golikova, the Council Chairperson.
In 2022, he was awarded the Medal of the Order of “For Merit to the Fatherland” II class for the COVID-19 vaccine development and production. He was also awarded the Letter of Appreciation from the Minister of Health of the Russian Federation for his honourable commitment to developing the medical and pharmaceutical sectors.
In 2023, he was awarded a Letter of Appreciation from the Russian Government for his contribution to national policy implementation and the development of charity and social guardianship.
Oxana is responsible for expanding the Group's presence in the Russian pharmaceutical market.
Prior to this appointment, Oxana successfully led the Consumer Healthcare business in Russia, implementing innovative OTC brand promotion strategies which resulted in double-digit growth, increased production capacity, an expansion of the product range, and a significant improvement in market position.
Oxana’s leadership has led to numerous consumer healthcare brands achieving the number one position in the marketplace.
Over the past 15 years, Oxana has held various management roles at Novartis Pharma, Sanofi and Glenmark. From 2014-2015, she served as Chairman of the OTC Board at the Association of International Pharmaceutical Manufacturers (AIPM).
Oxana Pozdnyakova holds an MBA in Marketing from California State University, Hayward, and has also studied at INSEAD Business School in France.
Born 1972
Nationality Russian
Professional career:
2014 - now Akrikhin Pharmaceuticals Co, president
2013 – 2014 Rosta – Russian pharmaceutical group Distribution, Executive Vice President
2002-2013 Teva Pharmaceutical Industries, General Manager Russia
2001-2002 Abbott Laboratories, director
1996-2000 La Roche, National Field Force Manager, Russia Roche Pharma
1995-1996 Organon pharma, Sales Representative, N.Novogord, Russia
Qualifications
1989-1996 N. Novgorod Medical Academy, Medical Doctor
After graduating from the Faculty of Journalism of Leningrad State University, Alexey worked in the field of public relations at the Town Hall and Administration of St. Petersburg city. After that, Alexey held senior positions in Russian Presidential Academy of National Economy and Public Administration under the President of the Russian Federation and FMCG market companies. He is one of the top 50 government relations directors. Since 2022 — Chairman of the Board of the Association of Pharmaceutical Manufacturers of the EEU.